What Barrett Hodgson does

Barrett Hodgson Pakistan (Pvt.) Ltd. is a Karachi-headquartered, private pharmaceutical company founded in 1992 and formally inaugurated in 1996. It operates as part of the Habib family enterprise and is owned by The Salim Habib Education Foundation (TSHEF), a non-profit established in 2007 that channels profits into educational initiatives including Barrett Hodgson University in Karachi and Barrett Hodgson College in Toba Tek Singh. The company ranks among the top 15 of approximately 700 pharmaceutical companies in Pakistan by turnover, with disclosed revenue of Rs. 11.28 Billion and a stated target of Rs. 20 Billion.

The company manufactures and distributes a portfolio of more than 100 brands and 240 formulations across cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, neurology, and other therapeutic areas; 24 brands lead their respective molecules. Approximately 5 of every 6 product representations originate from co-development partnerships with global MNCs, namely AstraZeneca (Losec, Plendil, Betaloc-ZOK), Astellas (Cefspan, Cefizox), Allergan (Lumigan, Alphagan, Combigan, Botox), LTL Pharma (cephalosporin range), and The Aenova Group (pain management). Manufacturing is cGMP-compliant with a Quality Management System based on ICH, WHO, and PIC/s guidelines; SAP S/4 HANA ERP was deployed in 2018 as the first such implementation in a Pakistani pharma company, and a new sterile area was approved by DRAP in 2020.

The business model is a prescription-driven pharma distribution business monetized through one-time product sales across Pakistan via a 1,100+ strong field force and 72 distributors reaching approximately 2,600 towns, 31,000 pharmacies, and 310+ hospital and institutional customers. Commercial operations are organized into therapeutic divisions led by Deputy Commercial Directors under a layered Area Manager / Regional Head structure, with supporting medical detailing, CME programs, patient awareness camps, and social media marketing. The company is currently expanding manufacturing capacity (sterile, tablet, liquid), constructing a Lahore warehouse, and acquiring a 2-acre plot in Karachi for portfolio diversification beyond pharmaceuticals, consistent with its growth trajectory and CSR commitments under TSHEF.

Name

Barrett Hodgson

Legal name

Barrett Hodgson Pakistan (Pvt.) Ltd.

Website

https://barretthodgson.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Barrett Hodgson Pakistan is a Karachi-based pharmaceutical company ranking among Pakistan's top 15, manufacturing and distributing over 100 brands and 240 formulations across cardiovascular, respiratory, ophthalmology, and pain management through a 1,100+ member field force.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Therapeutic formulations
• Cardiovascular drugs
• Cephalosporin antibiotics

Headquarters

HQ city

Karachi

HQ country

Pakistan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of pharmaceutical products across multiple therapeutic categories through direct sales force and distribution network covering 72 distributors, 2,600 towns, 31,000 pharmacies, and 310+ hospital/institution customers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Barrett Hodgson Pakistan manufactures and distributes a portfolio of over 100 pharmaceutical brands and 240 formulations across cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, and neurology therapeutic areas. The company also represents products from five global partners including AstraZeneca, Astellas, Allergan, LTL Pharma, and Aenova Group across Pakistan through a 72-distributor network covering 2,600 towns, 31,000 pharmacies, and 310+ hospital/institutional customers.

Product overview

Barrett Hodgson Pakistan (BHP) is a pharmaceutical company ranking among the top 15 in Pakistan with over 100 brands and 240 formulations. The portfolio includes products from five international business partners: AstraZeneca (cardiovascular/respiratory: Losec, Plendil, Betaloc-ZOK), Astellas (cephalosporin antibiotics: Cefspan, Cefizox), Allergan (ophthalmology: Lumigan, Alphagan, Combigan; and therapeutics/cosmetics: Botox), LTL Pharma (cephalosporin range), and The Aenova Group (pain management). Core products span therapeutic areas including cardiovascular, respiratory, anti-infective, ophthalmology, pain management, gastroenterology, diabetes, and neurology. 24 brands are market leaders. The company also operates through The Salim Habib Education Foundation (TSHEF) for CSR and education initiatives, and is diversifying into non-pharmaceutical businesses.

Differentiator

Problem solved

Functional benefit

Products and services

• Acicon
• AciReg Esomeprazole 20mg, 40mg Capsule and 40mg IV Infusion for proton pump inhibition; sold through Pakistan pharmacy and hospital distribution.
• Aerokast Montelukast sodium 4mg Sachet, 4mg and 5mg Chewable Tabs, 10mg Tabs for respiratory conditions; sold through Pakistan pharmacy and hospital distribution.
• Alphagan Ophthalmic Solution Brimonidine tartrate 0.2% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.
• Botox Botulinum Toxin Type A for therapeutic and cosmetic applications, distributed in Pakistan in partnership with Allergan.
• Febrol Paracetamol-based analgesic in Tablet, Suspension and DS Suspension forms for pain and fever management; distributed across Pakistan pharmacies.
• Inocef Ceftriaxone 250mg and 500mg IM Injection and 250mg, 500mg, 1000mg and 2000mg IV Injection for anti-infective therapy; supplied to Pakistani hospitals and pharmacies.
• Nebicare Nebivolol 2.5mg, 5mg and 10mg Tablet for cardiovascular conditions; launched in 2017 and sold through Pakistani pharmacy and hospital distribution.
• AV-Sartan Amlodipine+Valsartan combination tablet in 5mg+80mg, 5mg+160mg and 10mg+160mg strengths for hypertension; launched in 2017.
• Gutset Itopride Hydrochloride 50mg Tablet for gastrointestinal disorders; launched in 2017.
• Lumigan Ophthalmic Solution Bimatoprost 0.03% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.
• Combigan Ophthalmic Solution Brimonidine tartrate/Timolol maleate 0.2%/0.5% ophthalmic solution for glaucoma; marketed in Pakistan in partnership with Allergan.
• Cefspan Cefixime 100mg/5ml Suspension, 200mg/5ml DS Suspension and 400mg Capsule for anti-infective therapy; marketed in Pakistan in partnership with Astellas.
• Cefizox IV-IM Injection Ceftizoxime sodium 250mg, 500mg and 1000mg IV/IM Injection for anti-infective therapy; marketed in Pakistan in partnership with Astellas.
• Mobikare Diclofenac Sodium in Capsule, Injection, Plus Tablet, and Gel formulations for pain management; supported by Aenova Group partnership.
• Diabold Glimepiride 1, 2, 3 and 4mg Tablet for diabetes management; distributed through Pakistan pharmacy and hospital network.
• Baristat Febuxostat 40mg and 80mg Tablet for gout management; distributed through Pakistan pharmacy network.
• Rivaclot Rivaroxaban 2.5mg, 10mg, 15mg and 20mg Tablet for anticoagulation therapy; distributed through Pakistan pharmacy network.
• RosuBar Rosuvastatin 5mg, 10mg and 20mg Tablet for lipid management; distributed through Pakistan pharmacy network.
• Neugalin Pregabalin 25mg, 50mg, 75mg, 100mg and 150mg Capsule for neurological conditions including neuropathic pain.
• S-gliptin Sitagliptin and Sitagliptin+Metformin HCI combination tablet for diabetes management.
• Vilcret Plus Vildagliptin+Metformin HCI tablet in 50mg+500mg, 50mg+850mg and 50mg+1000mg strengths for diabetes management.
• AstraZeneca Brand Portfolio (Losec, Plendil, Betaloc-ZOK) Cardiovascular and respiratory products from partner AstraZeneca represented in Pakistan including Losec (Omeprazole), Plendil (Felodipine), and Betaloc-ZOK (Metoprolol succinate).
• Astellas Cephalosporin Range (Cefspan, Cefizox) Cephalosporin antibiotic products from partner Astellas including Cefspan (Cefixime) and Cefizox (Ceftizoxime sodium) in various injectable and oral formulations.
• Allergan Ophthalmology Brand Portfolio (Lumigan, Alphagan, Combigan, Botox) Ophthalmology and therapeutics products from partner Allergan including Lumigan (Bimatoprost), Alphagan (Brimonidine), Combigan (Brimonidine/Timolol), and Botox for therapeutic and cosmetic applications.
• LTL Pharma Cephalosporin Range Cephalosporin antibiotic range acquired from partner LTL Pharma Co., Ltd. (Japan) ensuring stable supply of original-quality products.
• Aenova Pain Management Portfolio Pain management products supported by partner The Aenova Group (Germany), a global contract manufacturer with 22 sites across Europe, Asia and USA.

Quantifiable outcome

• Ranked among top 15 pharmaceutical companies in Pakistan out of 700 companies
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• AstraZenecacoreStrategic or Co-development PartnerBritish-Swedish multinational pharmaceutical company with operations in more than 100 countries. BHP represents AstraZeneca in Pakistan through different therapeutic segments including Cardiovascular and Respiratory. Key brands marketed include Losec, Plendil, and Betaloc-ZOK.
• AstellascoreStrategic or Co-development PartnerJapanese pharmaceutical company formed in 2005 with merger of Yamanouchi and Fujisawa. BHP represents Astellas in Pakistan through Cephalosporin Antibiotics segment. Markets different formulations of Cefspan and Cefizox.
• AllergancoreStrategic or Co-development PartnerUS-based global multi-specialty ophthalmic healthcare company established in 1948. BHP markets Allergan's ophthalmology brands including Lumigan, Alphagan, Combigan, and Botox for therapeutics and cosmetics.
• LTL Pharma Co. Ltd.coreStrategic or Co-development PartnerJapanese subsidiary of Japan Established Medicine Corporation. Ensures stable supply of products maintaining original product reliability, quality, efficacy and safety. BHP acquires Cephalosporin range from LTL Pharma.
• The Aenova GroupcoreStrategic or Co-development PartnerGlobal leader in pharmaceutical and healthcare industries with emphasis on innovative technologies and high quality standards. One of the leading contract manufacturers in Europe operating 22 sites in eight European countries, Asia and USA. Supports BHP's Pain Management portfolio.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Ferozsons Laboratories: Listed Pakistani pharma company partnering with global MNCs (e.g., Gilead for hepatitis C); comparable MNC in-licensing model and branded generics portfolio.
• Highnoon Laboratories: Pakistani pharma manufacturer with strong primary care and chronic disease franchises; comparable mid-to-large field force and therapeutic breadth.
• PharmEvo: Pakistani pharma company with similar therapeutic breadth (cardio, diabetes, CNS) and large field force; competes head-to-head with BHP in chronic disease categories.
• Getz Pharma: Pakistan-based branded pharmaceutical manufacturer with a broad multi-therapeutic portfolio and large field force; one of the most direct top-15 competitors to BHP in cardiology, anti-infectives and gastroenterology.
• Hilton Pharma: Pakistani pharma manufacturer focused on branded generics across cardiovascular, anti-infective and CNS; similar scale and distribution-driven GTM model to BHP.
• AGP Limited: Top-tier Pakistani pharma manufacturer with strong cardiovascular, gastroenterology and anti-infective franchises; comparable therapeutic mix and hospital-channel focus.
• Bosch Pharmaceuticals: Pakistani pharma manufacturer competing in similar antibiotic, cardiac and respiratory categories; comparable scale and distribution-driven model.
• The Searle Company: Listed Pakistani pharma company with a comparable multi-therapeutic branded portfolio, in-licensed MNC brands and similar distribution model; directly competes with BHP across multiple therapy areas.
• Macter Pharma: Pakistan-based contract and branded pharmaceutical manufacturer with multi-therapeutic portfolio and strong export orientation; overlaps with BHP in manufacturing and product mix.

Broad incumbents

• Cipla: Global emerging-markets pharma major with a strong presence in respiratory, anti-infective and cardiovascular; serves as a broader incumbent benchmark for therapeutic mix, regulatory standards and pricing dynamics relevant to BHP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Barrett.Hodgsons
• LinkedInlinkedin.com/company/barrett-hodgson-pakistan

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barrett Hodgson